Monica Mita MD | NCICIRB

Dr. Monica Mita, MD

Claim this profile

Cedars-Sinai Medical Center

Expert in Breast Cancer
Studies Solid Tumors
21 reported clinical trials
35 drugs studied

Area of expertise

1

Breast Cancer

Global Leader

Monica Mita, MD has run 14 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
Stage III
2

Solid Tumors

Monica Mita, MD has run 9 trials for Solid Tumors. Some of their research focus areas include:

Stage IV
Stage III
HER2 negative

Affiliated Hospitals

Image of trial facility.

Cedars-Sinai Medical Center

Image of trial facility.

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

Clinical Trials Monica Mita, MD is currently running

Image of trial facility.

Evexomostat + Alpelisib + Fulvestrant

for Breast Cancer

This trial tests a new drug combination for post-menopausal women with a specific type of advanced breast cancer. It aims to see if the new drug can reduce side effects and improve the effectiveness of existing treatments. The treatment works by blocking proteins and hormones that help cancer grow and by managing side effects like high blood sugar.

Recruiting

1 award

Phase 1 & 2

11 criteria

Image of trial facility.

OBT076

for Advanced Cancer

The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authorities to be prescribed by doctors for the treatment of metastatic or recurrent solid tumors. The use of OBT076 in this study is investigational. This is a Phase I research study designed to look at several dose levels of the study drug to find the highest dose level that is safe and well-tolerated (does not cause unacceptable side effects), and to examine the effects of the study drug in a small group of research participants. The study will also look at the effectiveness of OBT076 as an anti-cancer therapy. Once the optimal dose is determined and safety is assessed, additional research participants will be treated at the optimal dose level to further evaluate safety and effectiveness.

Recruiting

1 award

Phase 1

15 criteria

More about Monica Mita, MD

Clinical Trial Related

9 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 5 Active Clinical Trials

Treatments Monica Mita, MD has experience with

  • Pembrolizumab
  • Nivolumab
  • Ladiratuzumab Vedotin
  • OBT076
  • Enobosarm
  • Abemaciclib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Monica Mita, MD specialize in?

Is Monica Mita, MD currently recruiting for clinical trials?

Are there any treatments that Monica Mita, MD has studied deeply?

What is the best way to schedule an appointment with Monica Mita, MD?

What is the office address of Monica Mita, MD?

Is there any support for travel costs?